Burroughs Wellcome Co.

Glaxo Wellcome Inc.

Devron R Averett

Thomas A Krenitsky

George Walter Koszalka

Thomas Spector

Eric C Bigham

Virgil L Styles

Robert W Morrison, Jr

Gerald Wolberg

Todd A Blumenkopf

Todd A Blumenhopf

Donald J Nelson

6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.

Tumor treatment with arabinofuranosyl purine derivatives

6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.

Therapeutic methods for using ARA-G derivatives

Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside

The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.

Antiviral combinations and compounds therefor

The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.

Synergistic combinations of nucleoside analogues, which are converted to viral DNA polymerase inhibitors through the action of at least one virus-induced enzyme, and thiosemicarbazone ribonucleotide reductase inhibitors are especially useful in combatting herpes virus infections.

Growing community of inventors

Raleigh, NC, United States of America

Devron R Averett